 Figure 
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For arriving at population estimates, sources of information include data from the World Health Organization (WHO), www.cancerresearchuk.org, and U.S. federal agencies such as National Institutes of Health (NIH), National Cancer Institute's SEER data base, and the Centers of Disease Control and Prevention (CDC), to name a few has been used. For the UK, data was extracted from the website of the ONS (Office of the National Statistics) and reports from NICE (National Institute of Clinical Excellence) and the NHS (the National Health Services). Where possible and practicable, the most recent data available have been used. Broad assumptions have been used with the intent to come up with best plausible estimates. Attempts have been made to reduce risks due to double counting (Exception: There is double counting of two applications selected for testing of Staphylococcus aureus. However, the inclusion of this data does not impact the share of these applications significantly in the total consumption amount. The assumptions are:
 It has been assumed that each product by a company for a particular application serves 100% of the market of the US and UK (i.e. no competition) and all patients, irrespective of socioeconomic status etc., have access to these products. For example, when a therapy is in clinical trials for head and neck cancer, we have used the latest publicly available data for number of people diagnosed with head and neck cancer in a particular year and used this data as a prospective population for treatment. Innovative medicines might create excitement with regard to possibility of increasing the life expectancy of a patient; hence we have assumed that all deaths could be prevented if this medicine is used as a last line treatment under the auspices of "expanded access or compassionate use" c . Therefore, mortality figures of people suffering from a particular type of cancer were used. We are aware that not all people will have access to these 'trial' drugs and devices, however, our objective is to model high emission worst case scenario and hence we have included these numbers. Various different disease types and stages of cancer have not been taken into consideration. It is assumed that all patients get treated in the same year, since the model (in the current state of development) doesn't allow for time-based-releases.
 Attempts have been made to reduce risks due to double counting (Exception: There is double counting of two applications selected for testing of Staphylococcus aureus). However, the inclusion of this data does not impact significantly the share of these applications in the total consumption amount.
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 Estimates of health and health care related statistics are based on the most recent data available in the public domain, except for incidences of Venous Thomboembolism for the UK.
 In most cases, dose of the therapeutic agent is used to arrive at estimates and the gold amounts that would be present in drug delivery equipments, containers containing the drug, etc. have not been included in our estimates.
 Census data of the US (2010) and UK (2011) have been used to arrive at the prospective population. The details of the data and assumptions used to calculate annual consumption of Au-NP from medical applications selected for the study is presented below. The two step approach:
1. Estimate the range of nano gold amount per application 2. Estimate the prospective affected population/total number of tests Assumptions for annual total number of tests  All women in the child bearing (15-44 yrs) age group conduct one pregnancy test per year. The age range of child bearing age has been taken from the reported age range of 15-44 yrs in Table  13 of the report Health, United States, 2011[6]  50% women of child bearing age group from (30-44 yrs) conduct 6 ovulation tests per year  20 million pregnancy and ovulation tests in the US per year [7]  Total female population, aged 15 to 44 yrs, for the US = 61606000 [8]  Total female population, aged 30-44 yrs, for the US = 30244000 [8]  Total female population, aged 15 to 44 yrs, for the U.K.= 12777000[9]  Total female population, aged 30-44 yrs,, for the U.K. = 6519000 [9] Assumptions for annual total number of tests Since this is a home based test based on oral fluids, we assume 50% of people from age 15 to 64 years conduct one home based HIV test per year, though legally the self-testing kit is to be sold to population aged 17 years or more, we have used 15-64 yrs because of the class intervals provided in the population tables. No. of discharges with septicaemia = 1665400. Around 15% (approx 250000) of the above discharges were diagnosed to be due to gram positive bacteria [17] 50% of patients suffering from septicaemia, the bacteria is unspecified. And, 15% have bacteria present in blood, but without the response. Keeping these factors into consideration, assume 30% more tests to be done. [17] Therefore, total no. of tests = 25000 + 30% of 250000. ca.325000
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UK:
No. of MSSA and MRSA reports in England (above 2 years of age) year 2013 = ca. 10000 [18] Population for England above 4 years is ca. 50 million[9].
Total population over 4 yrs for UK = ca. 60 million [9] So, for the UK = estimated number of MRSA and MSSA cases is 12000 (above 4 years of age) approx. = assume 15000 for all age groups. Therefore, total no. of tests = 15000 + 30% more tests = 15000 + 4500 = ca. 20000
D. Nasal decolonization of Staphylococcus aureus
Assumptions to estimate amount of Au per application 1. Au-NP size = 2 and 15 nm [19] 2. One vial = 1.5 ml, 54 vials in a pack [20] 3. Two treatments per patient [21] 4. 2nm Au-NP has ca. 270 atoms (M Au = 53000 Da) [22] 5. Mass of one Au-NP of 2 nm = 53000 dalton = 8. ) [19] . Use: 1 * 10 15 particles /ml. Therefore, no. of particles in 1.5 ml =1.5*10 15 8. 1 drop = approx. 0.05 ml 9. 8 drops per patient= 0.4 ml per patient. Therefore, no. of particles in 0.4 ml = 0.4*10 15 . Therefore, we use two estimates of Au per treatment for high emission scenario based on assumed particle size of 2 nm and 15 nm and volume of 0.4 ml and 1.5 ml:
 Amount per treatment (2 nm size)= 3.52*10 -5 g (0.4 ml) to 1.32*10 -4 g (1.5 ml)  Amount per treatment (15 nm size) = 1.36*10 -2 g (0.4 ml) to 5.12 *10 -2 g (1.5 ml) Assumptions for annual total number of tests 10-40% of population as outpatients or upon admission have nasal colonisation of S. aureus [23] ca. 2% -5% is the rate of Surgical Site Infections [24] We assume screening/treatment of 10% of the all surgical procedures (inpatients), because people with surgical procedures are at risk of contracting MRSA US -ca. 16 million surgical procedures conducted (2010) (short stay discharges with procedures from non federal hospitals) [25] Therefore, 10% of 16 million gives are the prospective number of patients treated = 1600000 for the US UK -Sum of Scotland, England, Wales and Northern Ireland =10% of (0. 25 Assumptions for annual total number of tests  10% of the population of the U.S. above 30 yrs of age will seek treatment for periodontitis  10% of the population of the U.K. above 15 yrs of age will seek per seek periodontitis treatment  Total population of the US above 30 years = 178474000 [8]  Total Population of the UK above 15 years of age = 52082000[9] [17] No. of discharges with gram negative bacterial incidences = 215000 [17] Assume, 30% more tests are done. Total no. of tests = 215000 + 30% of 215000 = 280000
Total no. of E-coli infections in England = 33336 for year 2013 [18] Assume 50000 for the UK for all gram negative infections Assume, 30% more tests are done. Therefore, total no. of tests for the UK= 30% of 50000 +50000 = 75000.
G.1.3. C. difficile infections (CDI)
336, 600 hospitalizations that involved CDI in 2009 [48] Assume 10% more diagnostic tests have been performed So, no. of tests/year for the US = 10% of 336600 +336600 = 370260
For England, reported cases is 13756 for the year 2013 [18] To estimate reported cases for CD infections for the UK, using the rate of 30 per 100000 of population = 18955 [18] Assume 10% more tests conducted [50] Assume, 8% of the white population will carry Factor V gene mutation US white population = 223553265 9 = 8% of 223553265 = 17884261
White population for England and Wales = 54809000 [51] = 8% of 54809000 = 4384720 = approx. 4400000
Estimated annual average of hospitalizations with VTE (≥18 years in the United States) = 547596 among those aged ≥18 years in the United States [52] 547596 hospitalisations shows 3% of the white population of the US who might carry one of the risk factors for VTE are hospitalised in a given year.
Therefore, we assume 5% of the white population of the US and UK gets the genetic test done.
5% of 4400000 for the UK = approx. 225000
G.3. Test kit for detection and genotyping Warfarin metabolism
Assumptions to estimate amount of Au per application For the US, VTE diagnosis = 547596 = approx. 550000 [52] 
H. Test To Establish Viral Load In HIV Patients
Assumptions to estimate amount of Au per application 
Type of cancer US UK
Estimated cases in 2014 [45] Estimated deaths for 2014 [45] 
Diagnosed Cases for 2011 Deaths in 2012
Colorectal 136830 50310 41581 [62] 16187 [62] Pancreatic 46420 39590 8773 [63] 8662 [63] Breast 235630 40430 50285 [64] 11716 [64] [45] Estimated deaths for 2014 [45] Diagnosed [67] 2119 (oral cancer) [67] Total 266650 [70] Therefore, assume 30% of the diagnosed population of all age groups take insulin = 6.3 million UK =3.2 million people have been diagnosed with diabetes (2013) [71] 10 http://www.nanospectra.com/clinicians/trialinfo.html: The clinical trials include metastatic lung cancer and refractory head and neck cancer 11 http://dtc.ucsf.edu/types-of-diabetes/type1/treatment-of-type-1-diabetes/medications-and-therapies/type-1-insulin-therapy/calculating-insulin-dose/ AF20 Also, assume 30% of UK's diabetic patients will take insulin (as derived from the American numbers) = 30% of 3.2 million = 960000 : total sludge treated agricultural land area in the UK [72]  0.2 m: the depth of agricultural soil [73]  408,139,000 acres is the total cropland/arable land in the US 12 = ca.1.65*10 12 m 2 [74, 75]  Total area of sludge treated soil the US: 1% [76] 12 1 acre = 0.004046 km 2 13 In the US, treated sewage sludge is termed as biosolids. (Table 104 ) [6] Average length of stay (both federal and non-federal hospitals) = 6.2 days (Table 108) The higher estimate of 5.35 million tonnes has been used in the study:  Due the futuristic perspective of nanomedicine waste  Increasing stringency in regulations concerning hospital waste We used Assessment Factors (AF) to account for chronic toxicity (AF time) and to extrapolate to no observed effect values (AF-no effect) for deriving the species sensitivity values. For short time or acute exposure studies, the factor used for AF time was 10. AF no-effect factor used was 1 for the concentration which showed no difference in comparison to the control treatment, AF no-effect factor used was 2, if L(E)C 10  L(E)Cx <L (E)C 50 and a factor of 10 was used to derive NOEC if 
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L(E) 50  L(E)Cx  L(E)C 100.
